ERBB2 and neoplasm: T-DXd has a higher drug to antibody ratio (DAR) than T-DM1 (8 vs. 3.5) and in preclinical gastric cancer models with HER2 overexpression demonstrated greater anti-tumour activity compared to T-DM1 [31–33].